IL17A and inflammatory bowel disease: To date, studies based on pooled data from clinical studies, observational studies, retrospective studies, and meta-analyses have not provided substantial detail regarding the clinical features of IBD induced by IL-17 inhibitors (Onac et al., 2021; Schreiber et al., 2019; Caron et al., 2022).